Neurological Institute

Tuesday, October 10, 2017

Nature Medicine study: Areas of glioblastoma tumors correlate with separate subtypes of glioma stem cells, respond better to combination treatment

CLEVELAND – A new study published in the Oct. 9 issue of the journal Nature Medicine demonstrates, for the first time, that glioblastoma (GBM), the most common and most lethal brain tumor, is driven by two distinct subsets of cancer stem cells.  Moreover, each subtype of glioma stem cells is driven by distinct transcriptional programs for growth and treatment resistance, and these different cell populations correspond to well-known morphological differences within the GBM itself. 
 
More importantly, the researchers found that while chemotherapeutic agents targeting each subtype achieve modest efficacy alone, they are synergistic when combined as demonstrated in a mouse model.
 
Senior co-author of the study, Andrew Sloan, MD, Medical Director, Brain Tumor and Neuro-Oncology Center at University Hospitals Cleveland Medical Center observed that GBMs typically have two radiologically distinct regions on MRI:  The enhancing mass and the necrotic core.  


Sunday, September 10, 2017

CWRU & University Hospitals Physician-Researcher Martha Sajatovic, MD, receives international brain health grant, joins team in new diabetes research project

CLEVELAND – Martha Sajatovic, MD, Professor of Psychiatry and of Neurology at Case Western Reserve University School of Medicine, Willard Brown Chair in Neurological Outcomes Research and Director of the Neurological and Behavioral Outcomes Research Center at University Hospitals Cleveland Medical Center, is the recent recipient of two major research grants.

As principal investigator (PI), Sajatovic will lead a National Institutes of Health (NIH) Fogarty International Center for Health grant in Tanzania with colleagues at Muhimbili University of Health and Allied Services to reduce the burden of chronic psychotic disorders using a customized adherence enhancement program combined with injectable, long-acting antipsychotic medication. The combined treatment approach was developed by Sajatovic’s team in Cleveland. Cleveland collaborators include Jennifer Levin, PhD, of UH and CWRU, and Carol Blixen, PhD, RN of CWRU. This grant is funded to CWRU for two years in the amount of $275,000.

 



Thursday, August 17, 2017

Ninth annual Northeast Ohio Parkinson’s Boot Camp

CLEVELAND – University Hospitals teaches Parkinson’s research, the benefits of exercise, medical and surgical therapies and more at its Ninth Annual Parkinson’s Boot Camp Sept. 9, 2017 at the John S. Knight Center, 77 E. Mill Street in Akron.
 
Parkinson's disease is defined as a disorder of the brain characterized by shaking (tremor) and difficulty with walking, movement, and coordination.
 
The Boot Camp is a free program that will run from 9:30 a.m. to 3 p.m. with registration and breakfast beginning at 8:30 a.m. Boot Camp offers exercise techniques, mind and body wellness practices and invigorating skills that helps people with Parkinson’s to better manage their disease. The Boot Camp will also offer a special session for care partners and family members.


Wednesday, May 17, 2017

DAWN trial results demonstrate dramatic reduction in disability from stroke up to 24 hours of onset

CLEVELAND – Results from the DAWN stroke trial presented at the European Stroke Organization Conference (ESOC) provide compelling evidence that selected patients suffering a major ischemic stroke recovered significantly better with mechanical retrieval of the blood clot with medical therapy compared with medical therapy alone when initiated past the current guidelines of within 6 hours and up to 24 hours of the stroke.
 
University Hospitals Cleveland Medical Center was one of the top seven recruiting sites in the multi-site study that enrolled a total of 206 patients in the nation. The results showed that patients treated with the retrieval system, known as mechanical thrombectomy, had significantly decreased post-stroke disability and improved functional independence at 90 days compared to medical management alone.


Friday, April 28, 2017

Dr. Andrew Sloan presents encouraging results of Laser Interstitial Thermal Therapy (LITT) clinical studies for difficult-to-access brain lesions

CLEVELAND – Andrew Sloan, MD, Director of the Brain Tumor and NeuroOncology Center at University Hospitals Cleveland Medical Center, presented new data supporting use of the NeuroBlate system for brain lesions at the 2017 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Los Angeles on April 26. 
 
Dr. Sloan, who is also Professor and Vice Chair of the Department of Neurosurgery at Case Western Reserve University School of Medicine, presented on Monteris Medical’s LAISE study results. He delivered an oral presentation titled “Laser Ablation in Stereotactic Neurosurgery (LAISE): A Multi-Institutional Retrospective Analysis of LITT for Glioma” which described the results of 97 patients whose lesions were ablated with the NeuroBlate system.
 
Of the lesions analyzed, 48 percent were deep-seated, 57.8 percent were considered inoperable, and 1 percent were not suitable for chemotherapy. 



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.